10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
Retrieved on:
Tuesday, March 26, 2024
PLEASANTON, Calif., March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. This assay enables researchers to measure the whole transcriptome from FFPE tissue sections at single cell-scale resolution.
Key Points:
- Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution
PLEASANTON, Calif., March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. - "Visium HD is a game-changer for spatial discovery research, and our team couldn't be more proud and excited to get this long-awaited product into the hands of our customers," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics.
- Combining the power of whole transcriptome spatial discovery with histological insights, Visium HD enables comprehensive characterization of FFPE tissue samples.
- Best-in-class sequencing-based spatial transcriptomics data: Map gene expression with precision and high confidence using a simple and robust workflow exclusively available on Visium CytAssist.